Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DiaPep277 Long-Term Extension in Type 1 Diabetes
NCT00644501Phase 3Completed
- Sponsor
- Andromeda Biotech Ltd.
- Start
- Sep 2008
- Primary completion
- May 2013
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of diapep277 in type 1 diabetes mellitus (T1D), sponsored by Andromeda Biotech Ltd. Primary endpoint: Preservation of endogenous insulin secretion/beta-cell function. Started Sep 2008; status: completed.
02
Drugs
diapep277
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT00644501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00644501.